A new partnership in biotech is pushing the boundaries of personalized cancer treatment by developing AI-guided peptide vaccines tailored to each patient’s unique tumor profile.
Using a powerful cloud-based platform, scientists can rapidly analyze tumor genetics and create custom vaccines that train the immune system to target cancer cells with precision.
Early use in Europe under a compassionate care program has shown promising results, including pain relief and improved quality of life in patients with advanced bone metastases.
The project combines personalized and off-the-shelf vaccine strategies, aiming for both precision and broad accessibility. Clinical trials are planned in the U.S., while real-world data collection continues in Europe. This approach could signal a shift from generic cancer therapies to individually engineered treatments with fewer side effects and greater efficacy.
Seminal Vesicle Invasion & Senescent tumor cells.
Aspirin and BAT
